The physico-chemical properties of alisamycin (1) are shown in Table 1 . High resolution FABmass spectrometry of alisamycin (1) showed an (M + H) + ion of mass 521.2276 which corresponded to a formula ofC29H33N2O7. This indicated a molecular formula of C29H32N2O7 for alisamycin (1) and an unsaturation number offifteen. TwoUVabsorption maximaat 276 and 315nm (MeOH) indicated extended unsaturation. Although alkaline pH had only a marginal effect on the UVspectrum, acidification shifted the maximaat 315 nm to 325 nm and increased the absorption intensities at both the wavelengths by about 14%, indicating a keto-enol tautomeric system2). IR frequencies at 3400, 1710 and 1670cm"1 indicated hydroxyl, carbonyl and amide groups and a broad band at 1610cm"1 indicated a polyene moiety. sonances were assigned by a proton-detected CH hexenone. A full confirmation was obtained by a proton-detected long-range CH shift correlation (HMBC) NMR experiment (Table 2) . Thus this amide proton showed 3/CH correlation to C-3 (3 126.36), C-l ((5 188.63); 2JCH correlation to C-l' 05 165.16), and could thereby be assigned to the 2-NH proton.
The more down field amide proton showed an exchange cross peak with the enolic proton in the NOESY spectrum and it also showedlong-range COSYcorrelation with the H-l 1 proton (3 7.32). In the HMBCspectrum this NH proton exhibited 3/CH correlation to the C-3" (3 174.15) and 2Jcn interaction to the C-l3 ( which was converted to its methyl ester (3) and subsequently identified by spectral analysis to be
These findings established a dienic upper side chain. Finally any ambiguity in the structure assignment of the terminal cycloalkyl substituent (i.e. cyclohexyl vs. methylcyclopentyl) was ruled out by HNO3 oxidation40 of alisamycin (1). The resulting acid on methylation afforded methylcyclohexanecarboxylate (4) which was found identical with an authentic sample by GC-MSanalysis. The occurrence of a cyclohexyl residue is in agreement with the biosynthetic pathways proposed for this class of antibiotics5).
In the case of asukamycin in particular, which has a 7-cyclohexyl-hept-2£,4is,6i?-trienoyl moiety as the upper side chain, the starter unit is reported to be a cyclohexyl-carbonyl-CoA, derived from the shikimate pathway, with chain extension by three molecules of malonyl-CoA. By direct analogy, it can be suggested that the biogenesis of the upper side chain of alisamycin (1) involves a starter unit of the shikimate derived cyclohexylcarbonyl-CoA, with chain extension by two malonyl-CoA molecules.
